Literature DB >> 2014951

The physiologic basis of diuretic synergism: its role in treating diuretic resistance.

D H Ellison1.   

Abstract

Diuretic drugs usually improve edema when used judiciously. Some patients, however, become resistant to their effects. Diuretic resistance may result from dietary indiscretion, poor compliance, impaired bioavailability, imparied diuretic secretion into the lumen of the renal tubule, or because other drugs interfere with diuretic activity. When easily treatable causes of diuretic resistance have been excluded, resistance often reflects the intensity of the stimuli to sodium retention. Recent experimental work has indicated ways in which the kidney adapts to chronic diuretic treatment and has indicated how these adaptations may limit diuretic effectiveness. First, nephron segments downstream from the site of diuretic action increase sodium-chloride (NaCl) reabsorption because the delivered NaCl load increases. Second, diuretic-induced contraction of the extracellular fluid volume stimulates kidney tubules to retain NaCl until the next dose of diuretic is administered. Third, kidney tubules themselves may become hypertrophic because they are chronically stimulated by diuretic-induced increases in NaCl delivery. These adaptations all increase the rate of NaCl reabsorption and blunt the effectiveness of diuretic therapy. When diuretic resistance is present, using a second diuretic drug that acts in a different nephron segment is often effective. Recent experimental results suggest that a second class of drug may act synergistically with the first by blocking the adaptive processes that limit diuretic effectiveness. On the basis of an understanding of the mechanisms of diuretic adaptation and resistance, treatment regimens can be designed to block specific adaptive mechanisms and to improve diuretic therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014951     DOI: 10.7326/0003-4819-114-10-886

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  52 in total

Review 1.  A practical guide to the management of hypertension in renal transplant recipients.

Authors:  A J Olyaei; A M deMattos; W M Bennett
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  [Modern differential therapy with diuretics].

Authors:  D Fliser; H Haller
Journal:  Internist (Berl)       Date:  2004-05       Impact factor: 0.743

Review 3.  Use of diuretics in cardiovascular diseases: (1) heart failure.

Authors:  S U Shah; S Anjum; W A Littler
Journal:  Postgrad Med J       Date:  2004-04       Impact factor: 2.401

4.  Oral Metolazone Versus Intravenous Chlorothiazide as an Adjunct to Loop Diuretics for Diuresis in Acute Decompensated Heart Failure With Reduced Ejection Fraction.

Authors:  Brian C Bohn; Rim M Hadgu; Hannah E Pope; Jerrica E Shuster
Journal:  Hosp Pharm       Date:  2018-08-30

Review 5.  Ventricular assist devices: pharmacological aspects of a mechanical therapy.

Authors:  O Wever-Pinzon; J Stehlik; A G Kfoury; J V Terrovitis; N A Diakos; C Charitos; D Y Li; S G Drakos
Journal:  Pharmacol Ther       Date:  2012-01-16       Impact factor: 12.310

6.  Optimal use of diuretics in patients with heart failure.

Authors:  Jigar Patel; Michael Smith; J Thomas Heywood
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

Review 7.  Pathophysiology and clinical presentations of salt-losing tubulopathies.

Authors:  Hannsjörg W Seyberth
Journal:  Pediatr Nephrol       Date:  2015-07-16       Impact factor: 3.714

Review 8.  A perspective on diuretic resistance in chronic congestive heart failure.

Authors:  Niel Shah; Raef Madanieh; Mehmet Alkan; Muhammad U Dogar; Constantine E Kosmas; Timothy J Vittorio
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-07-20

Review 9.  Right Heart Failure and Cardiorenal Syndrome.

Authors:  Thida Tabucanon; Wai Hong Wilson Tang
Journal:  Cardiol Clin       Date:  2020-03-02       Impact factor: 2.213

Review 10.  Loop Diuretics in the Treatment of Hypertension.

Authors:  Line Malha; Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.